Intravenous RPR109881 in Male or Female Patients With Advanced Breast Cancer Who no Longer Respond to Anthracycline, Taxane and Capecitabine Treatment
NCT00087958
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
168
Enrollment
INDUSTRY
Sponsor class
Conditions
Breast Cancer
Interventions
DRUG:
XRP9881
Sponsor
Sanofi